Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Biotechnology

Healthcare
$16.99 +0.58%

+$0.04 today

Market cap
$3.10B
Beta
0.90
P/E (TTM)
98.7
EPS (TTM)
$0.07
52W Low $4.40High $10.08

Volume 2.76M

Average 1.66M

XERS EBITDA Margin

EBITDA as a percentage of revenue.

Xeris Biopharma Holdings, Inc.NASDAQ: XERS

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 14.8%

EBITDA Margin was 14.8% in Q1 FY2026, up 12.8 pp from a year earlier. On a trailing-twelve-month basis it was 14.7%, up 16.6 pp year over year. Over 3 fiscal years it widened by 67.2 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 5 analysts of 10.0% for the fiscal year ending Dec 2026, up from 4.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
14.8%-1.6 pp QoQ
Last fiscal yearDec 2025
4.4%+11.2 pp YoY
LTMMar 2026
14.7%+16.6 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+12.8 pp+2.5 pp-10.3 pp
1 year+11.2 pp+5.7 pp-5.6 pp
3 years+67.2 pp+29.2 pp-38.0 pp
5 years+30.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
4.4%
Year-over-year change
+11.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How XERS compares with its peers on the latest reported figures

  • XERS's LTM Mar 2026 EBITDA Margin of 14.7% is the 2nd highest of the 6 companies compared; the peer median is 6.3%.
  • Its year-over-year change of +16.6 pp is the 3rd highest of 6, against a peer median of +9.1 pp.
  • Over three fiscal years its change of +67.2 pp compares with a peer median of +51.9 pp.
XERS Competitors Peer median
EBITDA Margin for XERS and competitors
Company Period LTM level YoY 3-year change
ASNDAscendis Pharma A/SLTM Sep 202621.5% +42.1 pp+1018.2 pp
XERSXeris Biopharma Holdings, Inc.LTM Mar 202614.7% +16.6 pp+67.2 pp
MNKDMannKind CorporationLTM Mar 20267.6% -20.1 pp+64.3 pp
ETONEton Pharmaceuticals, Inc.LTM Mar 20266.3% +9.1 pp+39.4 pp
CORTCorcept Therapeutics IncorporatedLTM Jun 20263.5% -14.4 pp-20.8 pp
SEPNSepterna, Inc.LTM Sep 2026-59.3% +282.9 pp—
MBXMBX Biosciences, Inc. Common StockFY2025— ——
GHRSGH Research PLCFY2025— ——
SPRBSpruce Biosciences, Inc.FY2025— ——
Peer median (excluding XERS) 6.3%+9.1 pp+51.9 pp

Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue49.59M110.25M163.91M203.07M291.85M
Cost of Revenue13.32M22.63M28.65M36.83M53.41M
Gross Profit36.27M87.61M135.27M166.24M238.43M
Gross Margin73.1%79.5%82.5%81.9%81.7%
Research & Development25.16M20.97M22.34M25.56M31.17M
Selling, General & Admin125.72M137.75M146.1M163.48M182.37M
Operating Expenses151.43M169.55M179.28M199.88M213.54M
Depreciation & Amortization1.88M12.67M13.16M12.63M12.16M
EBITDA(113.67M)(69.31M)(23.74M)(13.99M)12.71M
EBITDA Margin-229.2%-62.9%-14.5%-6.9%4.4%
Operating Income(115.16M)(81.94M)(44.01M)(33.65M)24.9M
Operating Margin-232.2%-74.3%-26.8%-16.6%8.5%
Interest Income313K2.58M4.75M5.32M4.74M
Interest Expense7.18M14.1M26.61M33.18M29.08M
Other Income / Expenses(7.57M)(14.14M)(19.49M)(23.46M)(24.34M)
Income Before Tax(122.73M)(96.08M)(63.5M)(57.1M)554K
Pre-Tax Margin-247.5%-87.2%-38.7%-28.1%0.2%
Income Tax Expense0(1.42M)(1.25M)(2.27M)0
Net Income(122.73M)(94.66M)(62.26M)(54.84M)554K
Net Margin-247.5%-85.9%-38.0%-27.0%0.2%
EPS (Basic)(1.55)(0.70)(0.45)(0.37)0.00
EPS (Diluted)(1.55)(0.70)(0.45)(0.37)0.00
Weighted Avg Shares79.03M135.63M137.67M146.77M160.43M
Weighted Avg Shares (Diluted)79.03M135.63M137.67M146.77M172.74M

Xeris Biopharma Holdings, Inc.

NASDAQ:XERS

Intrinsic Alpha fair value

Locked

Current Price

$16.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.